Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
June 05, 2025 18:38 ET Ā | Source: Xilio Therapeutics, Inc. Total gross…
Halia Therapeutics Completes Enrollment in Phase 2a Clinical Trial of HT-6184 for Myelodysplastic Syndrome (MDS)
LEHI, Utah, June 4, 2025 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical…
Addex Convenes Annual General Meeting 2025
June 03, 2025 01:00 ET Ā | Source: Addex Therapeutics Geneva, Switzerland, June…
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd (āAvistoneā), an innovative biotechnology company focused…
